Theme Member
Dr Laura Eadie

Contact

Phone: 08 812 84307

Email: laura.eadie@sahmri.com

Qualifications

B.Sc, Hons (First Class; Biomedical Science), The University of Adelaide

PhD in Medicine, The University of Adelaide

Research Focus

Acute Lymphoblastic Leukaemia (ALL) is an extremely heterogeneous disease with subtypes of patients exhibiting a diverse range of genetic mutations. Certain subtypes of ALL can be treated with drugs already in clinical use. Laura undertook her Fulbright fellowship (2016-2017) at St. Jude Children’s Research Hospital in Memphis, Tennessee where she learned mouse models of high-risk ALL. She also investigated the functional significance of mutations to the transcription factor MYB, which have recently been identified in T-ALL patients. Future work will expand on this utilizing xenograft and transgenic mouse models, with particular focus on T-ALL. This project aims to 1) model mechanisms of drug resistance and 2) develop models for newly discovered mutations in order to aid the development of novel targeted and/or combination therapeutic approaches. Ultimately, results will inform clinical practice, impacting significantly on response to therapy and overall survival of adults and children with high-risk ALL.

Publications

Eadie LN, Hughes TP, White DL. Patients with low OCT-1 Activity and high ABCB1 fold change have poor long term outcomes in response to tyrosine kinase inhibitor therapy (Leukemia, accepted Jan 2018)

Eadie LN, Dang P, Goyne JM, Hughes TP, White DL.2017. The drug transporter ABCC6 has a newly identified role in the transport of and resistance to Tyrosine Kinase Inhibitors (PLOS ONE, 13(1): e0192180)

Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. 2017. The allosteric inhibitor ABL001 is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. (Oncotarget, accepted Jan 2018,https://doi.org/10.18632/oncotarget.24393)

Eadie LN, Hughes TP, White DL. 2016. Response to “Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?”. Leukemia, 31(3): 769-770

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. 2017. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia, 31(1): 75-82.

Eadie LN, Hughes TP, White DL. 2016. ABCB1 overexpression is a key initiator of resistance to the Tyrosine Kinase Inhibitors nilotinib, imatinib and dasatinib. PLoS ONE. 11(8): e0161470

Eadie LN, Hughes TP, White DL. 2013. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib and dasatinib. Clinical Pharmacology and Therapeutics, 95 (3): 294-306.

White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP. 2013. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27 (5): 1201-1204.

Eadie LN, Saunders VA, Hughes TP, White DL. 2013. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia and Lymphoma, 54 (3): 569-578.

Eadie L, Hughes TP, White DL. 2010. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 24 (4): 855-857.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL. 2008. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12): 3881-3888.

Awards/Funding

2016 Channel 7 Children’s Research Foundation Project Grant

2015 Fulbright Postdoctoral Scholarship

2015 Endeavour Research Fellowship (unable to accept due to Fulbright award)

2013 Dean’s Commendation for Doctoral Thesis Excellence

2011 HSANZ Non-Member Travel Grant

2010 HSANZ Non-Member Travel Grant

2010 New Scientist Award for Science and Technology in Society

2009 Leukaemia Foundation of Australia PhD Scholarship

2009 Baillieu Supplementary Research Scholarship

2009 RAH / IMVS Research Committee Dawes Scholarship

2009 NHMRC Biomedical Postgraduate Scholarship (unable to accept)

2009 Australian Postgraduate Award (unable to accept)

2008 HSANZ Non-Member Travel Grant

2006 Australasian Society for HIV Medicine Junior Researcher Award

2006 RAH Research Committee Honours Scholarship

2005 Molecular Plant Breeding CRC Summer Scholarship

2004 Admittance to the Golden Key International Honour Society

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.